secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elevation Oncology, Inc. (—)
CIK:        0001783032
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001558370-24-006455
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elevation Oncology Q1 net loss $10.7M; cash $104.1M; EO-3021 trial ongoing
--------------------------------------------------------------------------

- Net loss of $10.7M improved from $17.1M in Q1 2023; R&D expenses $6.0M, G&A $3.9M.
- Cash and marketable securities $104.1M at March 31, 2024; raised $44.2M YTD via ATM, extending runway into 2026.
- Enrollment ongoing in Phase 1 trial of EO-3021 (Claudin 18.2 ADC); initial safety/efficacy data expected by mid-3Q 2024.
- Presented preclinical proof-of-concept for HER3-ADC program at AACR; development candidate nomination planned for 2H 2024.
- Plans to share details of EO-3021 combination study in 1H 2024; additional data expected in 1H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783032/000155837024006455/0001558370-24-006455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783032/000155837024006455/elev-20240502x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer